Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 28 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-2.83 Insider Own69.04% Shs Outstand37.66M Perf Week14.68%
Market Cap815.15M Forward P/E- EPS next Y-3.19 Insider Trans-0.30% Shs Float14.68M Perf Month11.99%
Income-107.79M PEG- EPS next Q-0.82 Inst Own30.32% Short Float3.03% Perf Quarter24.21%
Sales0.00M P/S- EPS this Y48.86% Inst Trans-0.54% Short Ratio2.64 Perf Half Y36.10%
Book/sh6.30 P/B2.73 EPS next Y-5.84% ROA-31.29% Short Interest0.44M Perf Year3.55%
Cash/sh6.84 P/C2.51 EPS next 5Y- ROE-36.80% 52W Range9.94 - 19.09 Perf YTD7.10%
Dividend Est.- P/FCF- EPS past 5Y- ROI-31.07% 52W High-9.95% Beta0.64
Dividend TTM- Quick Ratio17.58 Sales past 5Y0.00% Gross Margin- 52W Low72.94% ATR (14)0.75
Dividend Ex-Date- Current Ratio17.58 EPS Y/Y TTM50.88% Oper. Margin0.00% RSI (14)67.86 Volatility5.53% 4.68%
Employees62 Debt/Eq0.17 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price28.20
Option/ShortNo / Yes LT Debt/Eq0.16 EPS Q/Q-81.01% Payout- Rel Volume0.32 Prev Close17.41
Sales Surprise- EPS Surprise1.22% Sales Q/Q- EarningsNov 09 AMC Avg Volume168.14K Price17.19
SMA2013.60% SMA5013.32% SMA20018.75% Trades Volume54,211 Change-1.26%
Date Action Analyst Rating Change Price Target Change
Dec-13-23Initiated H.C. Wainwright Buy $28
Feb-22-24 11:27PM
Feb-05-24 04:05PM
Jan-18-24 07:00AM
Jan-08-24 07:00AM
Jan-03-24 06:28PM
01:01PM Loading…
Dec-19-23 01:01PM
Dec-05-23 09:48PM
Nov-30-23 09:55AM
Nov-21-23 11:03AM
Nov-14-23 12:00PM
Nov-09-23 04:05PM
Nov-01-23 04:48PM
Sep-26-23 04:01PM
Sep-25-23 07:00AM
08:05PM Loading…
Sep-19-23 08:05PM
Aug-24-23 10:40AM
Aug-14-23 05:08PM
Jun-07-23 09:55AM
May-22-23 09:55AM
May-12-23 04:05PM
May-09-23 07:00AM
Apr-25-23 06:45AM
HilleVax, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing novel vaccines. Its pipeline includes Norovirus and HIL-214. The company was founded by Maurice Hilleman and Tadataka Yamada on March 25, 2020 and is headquartered in Boston, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kohli AdityaDirectorFeb 22Sale15.056,00090,312843,776Feb 22 05:20 PM
Kohli AdityaDirectorFeb 21Sale14.926,00089,495849,776Feb 22 05:20 PM
Kohli AdityaDirectorFeb 20Sale14.886,00089,272855,776Feb 22 05:20 PM
Kohli AdityaDirectorFeb 12Sale15.326,00091,921861,776Feb 14 04:22 PM
HERSHBERG ROBERTSee RemarksFeb 08Sale14.9311,597173,161953,831Feb 12 07:47 PM
Kohli AdityaDirectorFeb 08Sale14.938,866132,383812,878Feb 12 08:06 PM
Borkowski AstridChief Medical OfficerFeb 08Sale14.933,93358,726161,260Feb 12 07:35 PM
Maltbie ShaneChief Financial OfficerFeb 08Sale14.933,57653,39540,656Feb 12 07:51 PM
Borkowski AstridChief Medical OfficerDec 15Sale15.5010,000155,000165,193Dec 18 05:34 PM
Borkowski AstridChief Medical OfficerDec 04Sale14.5010,000145,000175,193Dec 05 04:52 PM
Borkowski AstridChief Medical OfficerDec 01Sale14.2010,000142,000185,193Dec 05 04:52 PM
Borkowski AstridChief Medical OfficerNov 17Sale14.0010,000140,000195,193Nov 20 04:53 PM
Borkowski AstridChief Medical OfficerNov 08Sale13.005,00065,000205,193Nov 13 05:25 PM